Humabs BioMed SA - Product Pipeline Review - 2016

  • ID: 3746948
  • Company Profile
  • 44 pages
  • Global Markets Direct
1 of 4
Humabs BioMed SA - Product Pipeline Review - 2016

Summary

‘Humabs BioMed SA - Product Pipeline Review - 2016’, provides an overview of the Humabs BioMed SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Humabs BioMed SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Humabs BioMed SA
- The report provides overview of Humabs BioMed SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Humabs BioMed SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Humabs BioMed SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Humabs BioMed SA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Humabs BioMed SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Humabs BioMed SA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Humabs BioMed SA Snapshot

Humabs BioMed SA Overview

Key Information

Key Facts

Humabs BioMed SA - Research and Development Overview

Key Therapeutic Areas

Humabs BioMed SA - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Humabs BioMed SA - Pipeline Products Glance

Humabs BioMed SA - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Humabs BioMed SA - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Humabs BioMed SA - Drug Profiles

Monoclonal Antibody for HCMV Infections

Product Description

Mechanism of Action

R&D Progress

FI-6

Product Description

Mechanism of Action

R&D Progress

mAb-100

Product Description

Mechanism of Action

R&D Progress

mAb-114

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Dengue

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for HBV Infections

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Influenza B Infections

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Rabies

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Staphylococcus Aureus Infections

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders

Product Description

Mechanism of Action

R&D Progress

MPE-8

Product Description

Mechanism of Action

R&D Progress

NVB-71.4

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 1 for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 2 for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Epstein-Barr Viral Infection

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Viral Infections

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Zika Virus Infection

Product Description

Mechanism of Action

R&D Progress

Humabs BioMed SA - Pipeline Analysis

Humabs BioMed SA - Pipeline Products by Target

Humabs BioMed SA - Pipeline Products by Molecule Type

Humabs BioMed SA - Pipeline Products by Mechanism of Action

Humabs BioMed SA - Dormant Projects

Humabs BioMed SA - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Humabs BioMed SA, Key Information

Humabs BioMed SA, Key Facts

Humabs BioMed SA - Pipeline by Indication, 2016

Humabs BioMed SA - Pipeline by Stage of Development, 2016

Humabs BioMed SA - Monotherapy Products in Pipeline, 2016

Humabs BioMed SA - Partnered Products in Pipeline, 2016

Humabs BioMed SA - Partnered Products/ Combination Treatment Modalities, 2016

Humabs BioMed SA - Out-Licensed Products in Pipeline, 2016

Humabs BioMed SA - Out-Licensed Products/ Combination Treatment Modalities, 2016

Humabs BioMed SA - Phase II, 2016

Humabs BioMed SA - Phase I, 2016

Humabs BioMed SA - Preclinical, 2016

Humabs BioMed SA - Discovery, 2016

Humabs BioMed SA - Pipeline by Target, 2016

Humabs BioMed SA - Pipeline by Molecule Type, 2016

Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016

Humabs BioMed SA - Dormant Developmental Projects,2016

List of Figures

Humabs BioMed SA - Pipeline by Top 10 Indication, 2016

Humabs BioMed SA - Pipeline by Stage of Development, 2016

Humabs BioMed SA - Monotherapy Products in Pipeline, 2016

Humabs BioMed SA - Pipeline by Target, 2016

Humabs BioMed SA - Pipeline by Molecule Type, 2016

Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll